CL2014003290A1 - Formulación farmacéutica que comprende péptido derivado del hongo alternaria que contiene epítopo para linfocitos t; método para determinar si linfocitos t reconocen un polipéptido de la formulación farmacéutica; método para tratar alergia a alternaria y/o cladosporium; método para preparar la formulación; y péptidos. - Google Patents

Formulación farmacéutica que comprende péptido derivado del hongo alternaria que contiene epítopo para linfocitos t; método para determinar si linfocitos t reconocen un polipéptido de la formulación farmacéutica; método para tratar alergia a alternaria y/o cladosporium; método para preparar la formulación; y péptidos.

Info

Publication number
CL2014003290A1
CL2014003290A1 CL2014003290A CL2014003290A CL2014003290A1 CL 2014003290 A1 CL2014003290 A1 CL 2014003290A1 CL 2014003290 A CL2014003290 A CL 2014003290A CL 2014003290 A CL2014003290 A CL 2014003290A CL 2014003290 A1 CL2014003290 A1 CL 2014003290A1
Authority
CL
Chile
Prior art keywords
lymphocytes
pharmaceutical formulation
formulation
cladosporium
alternaria
Prior art date
Application number
CL2014003290A
Other languages
English (en)
Inventor
Roderick Peter Hafner
Paul Laidler
Pascal Hickey
Mark Larche
Original Assignee
Circassia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46582267&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014003290(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Circassia Ltd filed Critical Circassia Ltd
Publication of CL2014003290A1 publication Critical patent/CL2014003290A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Ecology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
CL2014003290A 2012-06-01 2014-12-01 Formulación farmacéutica que comprende péptido derivado del hongo alternaria que contiene epítopo para linfocitos t; método para determinar si linfocitos t reconocen un polipéptido de la formulación farmacéutica; método para tratar alergia a alternaria y/o cladosporium; método para preparar la formulación; y péptidos. CL2014003290A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1209868.7A GB201209868D0 (en) 2012-06-01 2012-06-01 Alternaria peptides

Publications (1)

Publication Number Publication Date
CL2014003290A1 true CL2014003290A1 (es) 2015-05-22

Family

ID=46582267

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014003290A CL2014003290A1 (es) 2012-06-01 2014-12-01 Formulación farmacéutica que comprende péptido derivado del hongo alternaria que contiene epítopo para linfocitos t; método para determinar si linfocitos t reconocen un polipéptido de la formulación farmacéutica; método para tratar alergia a alternaria y/o cladosporium; método para preparar la formulación; y péptidos.

Country Status (17)

Country Link
US (1) US20150098969A1 (es)
EP (1) EP2855515A1 (es)
JP (1) JP2015520771A (es)
KR (1) KR20150028788A (es)
CN (1) CN104507959A (es)
AU (1) AU2013269326A1 (es)
BR (1) BR112014029856A2 (es)
CA (1) CA2875130A1 (es)
CL (1) CL2014003290A1 (es)
EA (1) EA201492268A1 (es)
GB (2) GB201209868D0 (es)
HK (1) HK1201752A1 (es)
IL (1) IL235840A0 (es)
IN (1) IN2014DN10558A (es)
MX (1) MX2014014461A (es)
SG (1) SG11201407975TA (es)
WO (1) WO2013179043A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3003365A1 (en) * 2013-06-05 2016-04-13 Maria R. Diaz-Torres T cell epitopes derived from alt a 1 or alt a 5 for the treatment of alternaria alternata allergy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT400723B (de) * 1993-08-27 1996-03-25 Biomay Prod & Handel Rekombinante alternaria alternata allergene
JP2007176953A (ja) * 1996-03-10 2007-07-12 Meiji Milk Prod Co Ltd アレルギー疾患に対するペプチド免疫療法剤
JP2003116556A (ja) * 2001-10-09 2003-04-22 Nippon Zenyaku Kogyo Kk アレルギー性皮膚炎治療剤
AT503690A1 (de) * 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
CA2696563A1 (en) * 2007-08-15 2009-02-19 Circassia Limited Peptides for vaccine
GB0821806D0 (en) * 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
EP2619219B1 (en) * 2010-09-24 2015-11-18 Alergenetica SL Peptides

Also Published As

Publication number Publication date
JP2015520771A (ja) 2015-07-23
IL235840A0 (en) 2015-01-29
US20150098969A1 (en) 2015-04-09
EA201492268A1 (ru) 2015-05-29
GB2517871A (en) 2015-03-04
MX2014014461A (es) 2015-02-10
WO2013179043A1 (en) 2013-12-05
AU2013269326A1 (en) 2014-12-18
EP2855515A1 (en) 2015-04-08
KR20150028788A (ko) 2015-03-16
CN104507959A (zh) 2015-04-08
HK1201752A1 (en) 2015-09-11
SG11201407975TA (en) 2015-01-29
GB201209868D0 (en) 2012-07-18
CA2875130A1 (en) 2013-12-05
IN2014DN10558A (es) 2015-08-21
BR112014029856A2 (pt) 2017-07-25

Similar Documents

Publication Publication Date Title
MA41294A (fr) Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation
HK1254755A1 (zh) 抗-肌肉生長抑制因子抗體、包含變體fc區的多肽及使用方法
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
IL251462A0 (en) Pharmaceutical formulations for oral administration of peptide or protein drugs
MX2018005720A (es) Anticuerpos pd-l1, fragmento de union al antigeno del mismo, y aplicacion medica de ello.
CL2014001994A1 (es) Polipeptido mimético de apelina sintéticos para el tratamiento e insuficiencia cardiaca; composicion farmacéutica que comprende dicho polipeptido.
NZ630542A (en) Methods of treating a tauopathy
WO2014139476A8 (zh) Rsv融合蛋白的表位以及识别其的抗体
IL262568A (en) Inactive material based on proteins for active pharmaceutical ingredients
IL247551B (en) A peptide drug in the form of a dry powder
HUE047156T2 (hu) Peptidek, eszközök és eljárások Anaplasma-ellenanyagok kimutatására
HK1254818A1 (zh) 抗原肽及其用於診斷和治療自閉症的用途
CU24453B1 (es) Anticuerpos anti proteína similar a angiopoyetina 4
ZA201800470B (en) An oral pharmaceutical dosage form for the delivery of a peptide and/or protein
MA42312A (fr) Particules de type virus recombinantes utilisant la protéine gag du virus de l'immunodéficience bovine
GB2546439B (en) Ezrin-derived peptides and pharmaceutical compositions thereof
WO2016007919A3 (en) Antibody fragments for detecting cancer and methods of use
CL2014003290A1 (es) Formulación farmacéutica que comprende péptido derivado del hongo alternaria que contiene epítopo para linfocitos t; método para determinar si linfocitos t reconocen un polipéptido de la formulación farmacéutica; método para tratar alergia a alternaria y/o cladosporium; método para preparar la formulación; y péptidos.
DK3450448T3 (da) Terapeutisk peptid til excitatorisk neurotoksicitets-relaterede skader
CL2014003289A1 (es) Péptido de cladosporium que contiene epítopo para linfocitos t; formulación farmacéutica que lo comprende; método para determinar si linfocitos t reconocen al péptido; método para tratar alergia a alternaria y/o cladosporium; y método para preparar la formulación.
MA48780A (fr) Peptides antagonistes de pac1
WO2016209959A3 (en) T cell epitope peptide combinations of cry j 1 and cry j 2 and use thereof in treating japanese cedar pollen allergy
IT201600083753A1 (it) Immunosaggio per l’identificazione di anticorpi contro il virus Polioma BK (BKPyV) mediante l’uso di peptidi sintetici.
ZA201607182B (en) Polypeptides for generating anti-influenza antibodies and uses thereof
UA32854S (uk) Опаковання для пластівців з висівками «beauty menu»